Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.

Inclusion Criteria:

* Must be 18 years or older
* Must have a performance status of at least 70% (able to carry on most normal activities)
* Must have life expectancy of at least 3 months
* Must have adequate organ and marrow function as determined by lab tests
* Women of child-bearing potential and men must agree to use two forms of contraception
* Ability and willingness to sign a written informed consent document
* Histologically confirmed solid tumor malignancy that is metastatic or unresectable

Exclusion Criteria:

* Pregnant or breastfeeding and/or lactating women
* Patients who have received any other investigational agents within 28 days of the first day of study drug
* Patients with known CNS metastases
* History of other carcinomas within last 5 years (except non-melanoma skin cancer, in-situ cervical cancer, localized prostate cancer)
* Inadequately controlled hypertension
* Significant vascular disease
* Invasion or encasement of a major artery
* Evidence of bleeding diathesis or coagulopathy
* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to day 1 of study drug
* Serious illness or medical condition
* History of myocardial infarction, unstable angina, cardiac or other vascular stenting
* History of stroke
* HIV, Hepatitis C, Hepatitis B or other serious chronic infection
* Impairment of Gastrointestinal function or disease
* History of interstitial lung disease
* Patients who have had radiation therapy, hormonal therapy, biologic therapy or chemotherapy for cancer within 28 days of receiving study drug.